Feature | September 04, 2012

Medtronic Completes High-Risk Patient Enrollment in CoreValve U.S. Pivotal Trial

FDA grants approval for intermediate-risk patients in global SURTAVI trial

Sept. 4, 2012 — Medtronic has reached two clinical program milestones for its CoreValve transcatheter aortic valve system in the United States. It completed enrollment in its study of high-risk patients in its CoreValve U.S. Pivotal Trial, which concludes the total trial enrollment of more than 1,500 patients with severe aortic stenosis who are at high- or extreme-risk for aortic valve surgery. Medtronic continues to enroll extreme-risk patients in the trial as part of the U.S. Food and Drug Administration (FDA) continued access policy and is seeking approval to continue enrolling high-risk patients under this policy.

In addition, Medtronic received FDA conditional approval to begin evaluating the CoreValve System in patients at intermediate risk for open-heart aortic valve replacement as part of the Medtronic CoreValve Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial. U.S. patient enrollment is expected to begin within weeks.

“With a sizeable population of Americans with severe aortic stenosis who have varying degrees of risk for open-heart aortic valve replacement surgery, the CoreValve U.S. Pivotal Trial and SURTAVI Trial are landmark trials that will provide critical insights about the appropriate use of the self-expanding CoreValve System,” said David H. Adams, M.D., chair of the department of cardiothoracic surgery at The Mount Sinai Medical Center and national co-principal investigator of both the CoreValve U.S. Pivotal Trial and SURTAVI Trial. “We are optimistic and eager to fulfill the requirements of both trials with the goal of effectively demonstrating the value of CoreValve as an alternative to open-heart valve replacement surgery.”

The CoreValve U.S. Pivotal Trial has enrolled more than 1,500 patients in two studies (high- and extreme-risk) led by heart teams made up of interventional cardiologists and cardiac surgeons at 45 leading clinical institutions across the United States.  Approximately two-thirds of trial patients are in the high-risk study. The primary endpoint for the high-risk study is freedom from all-cause death at 12 months, and the primary endpoint for the extreme risk study is freedom from all-cause death or major stroke within 12 months.

The SURTAVI Trial is the largest global, randomized, controlled trial on transcatheter aortic valve implantation (TAVI) and will evaluate approximately 2,500 patients. The trial will evaluate the potential for the minimally invasive CoreValve system to be considered for less-sick patients who typically are treated with open-heart surgical aortic valve replacement today (SAVR). Within the SURTAVI Trial, CoreValve implantation can be performed by transfemoral, subclavian or direct aortic access, depending on the needs of the patient. Selection of intermediate risk surgical patients will be based on the Society of Thoracic Surgeons (STS) mortality risk of ?4 percent and ?10 percent and the study’s primary endpoint will be a composite of all-cause mortality and disabling stroke at 24 months. All patients will be followed through five years. U.S. principal investigators are Adams; Jeffrey Popma, M.D., director, interventional cardiology at the Beth Israel Deaconess Medical Center, Boston; and Michael Reardon, M.D., chief of cardiac surgery at the Methodist DeBakey Heart and Vascular Center, Houston.

Since 2007, the Medtronic CoreValve System has been implanted in more than 30,000 people in more than 60 countries outside the United States.

For more information: www.clinicaltrials.gov

 

Related Content

News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
Lotus Edge Valve, CE mark, boston scientific, TAVR, TAVI

The Lotus Edge system in its deployed position. The Lotus valve expands outward as it is compressed and buckled in the deployment position. It also has a skirt to help eliminate paravalvular leaks.

News | Heart Valve Technology| September 19, 2016
September 19, 2016 — Boston Scientific received European CE mark approval for its Lotus Edge Valve System, the compan
Overlay Init